Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose-ranging Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Monthly And Twice Monthly Subcutaneous Dosing For Six Months In Hypercholesterolemic Subjects On A Statin

NCT01592240 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01592240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01592240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose-ranging Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Monthly And Twice Monthly Subcutaneous Dosing For Six Months In Hypercholesterolemic Subjects On A Statin
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2012
Completion date
May 31, 2013
Enrollment
354 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia